SGLT2 Inhibitor
SGLT2 Inhibitors for Non-Alcoholic Fatty Liver Disease
Recruiting0 awardsPhase 2
Minneapolis, Minnesota
This trial tests empagliflozin, a medication that helps remove extra sugar through urine, in adolescents with obesity and a specific liver condition (NAFLD). The medication works by blocking a protein in the kidneys to help remove sugar from the body. Empagliflozin has been shown to reduce body weight, improve glucose tolerance, and decrease blood pressure in various studies.
Vitamin E Derivative
Tocotrienol for End Stage Liver Disease
Recruiting0 awardsPhase 2
Indianapolis, Indiana
This trial is to see if a previous trial's results were accurate- that Tocotrienol (TCT) could help end stage liver disease / cirrhosis patients by taking 2 capsules of it (200mg) or placebo twice a day for 3 years.
Statins for Non-alcoholic Steatohepatitis (NASH)
Recruiting0 awardsPhase 2
Durham, North Carolina
This trial will test whether or not a daily dose of atorvastatin (a type of statin) is effective in treating NASH and hepatic fibrosis, and whether it is safe. The results of this study will help design a larger study on the matter.
Popular Filters
Trials for NAFLD Patients
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
Recruiting1 award
Boston, Massachusetts
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Thiazolidinedione
Low-Dose Pioglitazone for NASH
Recruiting1 awardPhase 2
Gainesville, Florida
This trial is testing a small daily dose of pioglitazone in patients with type 2 diabetes and a specific liver condition called NASH. The goal is to see if this medication can improve their liver health by helping their bodies manage blood sugar and fat levels better.
Resmetirom for Fatty Liver Disease
Recruiting1 awardPhase 3
Chandler, Arizona
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
Trials for Non-alcoholic Fatty Liver Disease Patients
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
Recruiting1 award
Boston, Massachusetts
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Thiazolidinedione
Low-Dose Pioglitazone for NASH
Recruiting1 awardPhase 2
Gainesville, Florida
This trial is testing a small daily dose of pioglitazone in patients with type 2 diabetes and a specific liver condition called NASH. The goal is to see if this medication can improve their liver health by helping their bodies manage blood sugar and fat levels better.
Resmetirom for Fatty Liver Disease
Recruiting1 awardPhase 3
Chandler, Arizona
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
Phase 3 Trials
Resmetirom for Fatty Liver Disease
Recruiting1 awardPhase 3
Chandler, Arizona
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
Thyroid Hormone Receptor Agonist
Resmetirom for Non-alcoholic Fatty Liver Disease
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying the safety and tolerability of Resmetirom, a pill taken regularly. It involves patients who are already using this medication. Resmetirom helps manage certain health conditions by targeting specific parts of the body and has shown to reduce liver fat in patients with non-alcoholic steatohepatitis (NASH) in previous studies.
Hormone Therapy
Estrogen Therapy for NASH in Postmenopausal Women
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial will study the effect of the hormone estradiol on non-alcoholic steatohepatitis (NASH) in post-menopausal women. NASH is a growing epidemic in the United States with limited treatment options.
Semaglutide for Non-alcoholic Steatohepatitis
Recruiting1 awardPhase 3
Madison, Alabama
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Growth Factor
Efruxifermin for NASH
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Trials With No Placebo
Behavioural Intervention
Diabetes Prevention & Education for Prediabetes
Recruiting1 award2 criteria
Baltimore, Maryland
This trial aims to reduce risk of type 2 diabetes in people with pre-diabetes by increasing access to lifestyle interventions. We will also study changes in body fat & liver fat in those who complete the program.
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
Recruiting1 award
Boston, Massachusetts
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Cardiac Glycoside
Digoxin for Alcoholic Hepatitis
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing whether a drug called digoxin is effective at treating people with severe alcohol-related liver damage. Patients will be given the drug or a placebo and monitored to see if their liver damage improves.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.